Download Tweetroducing bioZhena in 8 slides

bioZhena Corporation
Private Placement Offering
and/or
Strategic Alliance Proposal
8/3/2017
bioZhena Corporation
1
Target Customers’ Profile
30%
Sub-fertile
70%
Birth control
100%
Cervical health
cancer, STDs
Three statistics tell the story
Personalized medicine - diagnostic tools
$232 Billion personalized medicine market to grow 11% annually
said PricewaterhouseCoopers
bioZhena Corporation
70% of women “would switch”
70% of women who would buy the Ovulona Smart Sensor,
would switch from their current birth control to our fertility
status monitor [from a survey of 5,000 US women]
bioZhena Corporation
Cervical Cancer/STD Screen
Innocuous affordable triage for colposcopy-biopsy
Billions women globally.
Tens of millions reproductive-age
women in the U.S. alone.
This screen is for everyone.
Affordable. Private. Solid.
As the sensor monitors cervical tissues, other STDs will be detected.
Sexually Transmitted Diseases
bioZhena Corporation
Friendly Technology
From Home
to
Healthcare Providers
From patients’ Ovulona™ units to
physician’s Ovulograph™
– when needed
bioZhena Corporation
Applications, apps
Helping to Conceive
Pregnancy
Managing Menstrual
Cycle
Natural Birth Control
Managing Menopause
Cervical Cancer, STD
Screening
bioZhena Corporation
Total Available Market
Cervical cancer screening is an estimated
annual $5B US Pap smear test market.
Worldwide extrapolation: >$100B annually.
Ovulona™ will save an est. 50% - 90%.
Segments of bioZhena’s target market:
Trying to Conceive Pregnancy Market
Managing Menstrual Cycle Market U.S.
Birth Control Market
World
Managing Menopause Market
Cervical Health Screening Market
8/3/2017
bioZhena Corporation
~$ 25B
>$500B
7
bioZhena Corporation’s Offering
Personalized
Health
Management
bioZhena Corporation
Contact [email protected]